Science
Mechanism of Action
This advanced tripeptide operates via a dual-action pathway to effectively reduce melanin production. Firstly, it directly inhibits tyrosinase, a key enzyme essential for melanin synthesis, thereby preventing the formation of new pigment. Secondly, it downregulates the expression of MITF (microphthalmia-associated transcription factor), which is crucial for the differentiation and proliferation of melanocytes—the cells responsible for producing melanin. This comprehensive inhibition significantly diminishes hyperpigmentation. Its small molecular size ensures optimal skin permeability and an enhanced penetration rate, further boosting its efficacy. Additionally, it exhibits anti-inflammatory and anti-allergic properties.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 Clinical observations indicate that Tranexamoyl Dipeptide-23 demonstrates superior skin whitening activity when compared to established brightening agents such as Arbutin and Ascorbyl Glucoside.
Transparency
Dusting Analysis
The Formula
Formulation
Stability
The integration of a Tranexamic Acid (TXA) modification within Dipeptide-23 is designed to enhance its stability within cosmetic formulations, optimizing its long-term effectiveness.
Safety
Safety Profile
Cytotoxicity studies suggest that Tranexamoyl Dipeptide-23 is a safe ingredient for use in skincare formulations. While specific official reviews from regulatory bodies such as CIR, SCCS, or FDA are not yet available, its observed compatibility with sensitive skin further supports a favorable safety profile.
Your Skin
Skin Compatibility
Our Assessment
Verdict
TRANEXAMOYL DIPEPTIDE-23 stands as a valuable ingredient for advanced skin brightening, leveraging a powerful dual mechanism to effectively reduce various forms of hyperpigmentation, all while maintaining excellent skin compatibility, especially for sensitive skin.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources